tirzepatide pregnancy risk Does Cause Birth Defects? Evidence and Safety Guidance Tirzepatide & Pregnancy: Safety Facts

Clinical Evidence Linking GLP-1 Therapy to Improved Fertility Outcomes While large randomized fertility trials specifically testing GLP-1 compounds remain limited, retrospective data from weight loss studies show significant fertility improvements in people who lost 15% or more of body weight

Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model

these should be reported to healthcare providers for appropriate investigation

Peptide impurities and the characterization of active ingredients also pose challenges

In clinical trials, Mounjaro produced weight loss of up to 22.5% of body weight at 72 weeks (SURMOUNT-1), while Victoza typically produces about 3% body weight loss